Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

NHS bowel cancer checks reach record-high following death of Dame Deborah James

Between May and July 2022, over 170,500 people were referred for suspected lower gastro-intestinal cancers – up over 30,000 compared to the same period last year

- PMLiVE

Environment: where does the pharmaceutical industry stand?

Industry is taking environmental commitments more seriously, especially after pivotal events such as COP26 and publication of the IPCC’s cautionary ‘now or never’ report.Pharma is no exception, with some of...

- PMLiVE

Moderna’s Omicron booster receives MHRA approval

The booster dose can be used in adults aged 18 years and over to protect against contracting COVID-19

- PMLiVE

NHS England outlines measures to boost capacity ahead of substantial winter pressures

The package of measures includes creating the equivalent of 7,000 additional hospital beds

- PMLiVE

Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health

Charities have called on the government to reassess its decision, which could affect the immunocompromised

- PMLiVE

New research shows drug candidate may effectively treat antibiotic-resistant bacteria

Research published in The American Chemical Society Central Science journal has shown that Fabimycin may be effective against more than 200 antibiotic-resistant bacteria

- PMLiVE

Sanofi and NIHR enrol first patient in immunisation study for RSV in infants

RSV is the leading global cause of infant hospitalisation and affects 90% of children under the age of two

- PMLiVE

That ‘don’t’ impress me much

I am going to come straight out with it – when it comes to evaluation, I am not impressed by impressions.By the time you are reading this, many of you...

- PMLiVE

AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug

A phase 2 trial demonstrated an overall response rate of 57.7% in patients with non-small cell lung cancer

- PMLiVE

Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer

The approval for the treatment applies to England, Scotland and Wales

- PMLiVE

Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies

The companies will work together to develop new therapies to re-establish immune tolerance and repair tissue for those with inflammatory bowel diseases

- PMLiVE

Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older

It is the first and only single-dose oral medicine for this indication in children as young as five

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links